Department of Dermatology and Venereology, University Hospital "Alexandrovska," Medical University-Sofia, Sofia, Bulgaria.
Department of Dermatology and Venereology, University Hospital "Alexandrovska," Medical University-Sofia, Sofia, Bulgaria.
Clin Dermatol. 2021 May-Jun;39(3):359-368. doi: 10.1016/j.clindermatol.2021.01.007. Epub 2021 Feb 2.
Since the beginning of the COVID-19 outbreak, attention has gradually moved from the respiratory manifestations of the disease toward its dermatologic aspects. The need for wearing personal protective measures and their cutaneous side effects, detection of related or specific COVID-19 skin eruptions, and the evaluation of certain risk groups of immunosuppressed dermatologic patients have initiated significant discussions about various therapeutic interventions and, in particular, about biologic therapy for psoriasis and for autoinflammatory, orphan, or malignant cutaneous disorders. Autoimmune bullous dermatoses have been of concern due to their chronic course, at times life-threatening prognosis, and the need for prolonged and often aggressive immunomodulatory therapy. We have summarized the current knowledge regarding the impact of COVID-19 infection on autoimmune bullous dermatoses, including recommendations for the main treatment strategies, available patient information, and the registries organized for documentation during the COVID-19 pandemic.
自 COVID-19 疫情爆发以来，人们的关注焦点逐渐从疾病的呼吸道表现转向其皮肤科方面。由于需要佩戴个人防护措施及其皮肤副作用，发现与 COVID-19 相关或特定的皮肤疹，以及评估某些免疫抑制性皮肤病高危人群，人们对各种治疗干预措施进行了广泛讨论，特别是针对银屑病和自身炎症性、孤儿或恶性皮肤病的生物治疗。自身免疫性大疱性皮肤病受到关注，因为它们具有慢性病程、有时危及生命的预后，以及需要长期、通常是激进的免疫调节治疗。我们总结了 COVID-19 感染对自身免疫性大疱性皮肤病的影响的现有知识，包括对主要治疗策略的建议、现有的患者信息，以及在 COVID-19 大流行期间为记录而组织的登记处。
